BioNetwork 2017

October 23-October 25, 2017

The Ritz-Carlton, Laguna Niguel, CA

1.888.482.6012

Day 1: Monday, October 23, 2017

07:30 AM - 08:30 AM Registration and Breakfast

08:30 AM - 08:35 AM Welcome Remarks

08:35 AM - 08:50 AM Chairperson’s Opening Remarks

Jonathan Gertler, Managing Partner, CEO, Back Bay Life Science Advisors

img

Jonathan Gertler

Managing Partner, CEO
Back Bay Life Science Advisors

08:50 AM - 09:20 AM Opening Guest Keynote: A Wake Up Call to Drug Companies from Your Friendly Neighborhood Payer

Kent Rogers, SVP, Industry Relations, OptumRx, UnitedHealth Group
Having spent 20 years working in Pharma, Kent Rogers knows first-hand that the industry lacks a fundamental understanding of the payer landscape -- who payers are, what they do, and most importantly, what drugmakers need to know. Now as an executive at one of the largest payers in the country, Kent can offer a unique perspective into the complex Pharma/Payer environment and what the shifting dynamics mean for drug pricing. As Senior Vice President of Industry Relations for OptumRx, a division of Optum under the United Health Group enterprise, Kent's team is responsible for over $600M in procurement of brand, generic and specialty drugs, all contracting for rebate management of $80B in annual drug spend for all books of internal and external business with United Health Group. His talk will address:

Understanding each other’s business: what Pharma needs to know about the payer business prior to commercialization, and visa versa
Engaging in a dialogue, starting with what payers need from drug companies
Timelines: when should your team start have a reimbursement plan in place? At what point are you falling behind?
Top payer trends to pay attention to in 2018 and beyond


img

Kent Rogers

SVP, Industry Relations
OptumRx, UnitedHealth Group
1. Oncology

2. Immunology
Kia Motesharei, VP, Global Head of Business Development; Neurology & Immunology Global Business Development & Alliance Management; EMD Serono

3. Immuno-oncology

4. Rare and Orphan Diseases
Joe Whalen, SVP, Business Development & Alliance Management; Horizon

5. Pain

6. Gene Therapy
Greg Fond, Director, External Innovation, Sanofi

7. Diabetes

8.CNS & Neurodegenerative Diseases
Murali Gopalakrishnan, Senior Director & Head Search & Evaluation Neuroscience, Abbvie

9. Infectious Diseases


img

Greg Fond

Director, External Innovation
Sanofi
img

Kia Motesharei

VP, Global Head of Business Development, Neurology & Immunology Global Busi
EMD Serono
img

Joe Whalen

SVP, Business Development & Alliance Management
Horizon
img

Murali Gopalakrishnan

Senior Director & Head Search & Evaluation Neuroscience
Abbvie

09:50 AM - 10:20 AM Biotech Spotlights

Grace Colon, CEO, InCarda Therapeutics

img

Grace Colon

CEO
InCarda Therapeutics
  • What does the change in FDA leadership mean for pharma?
  • Changes in federal funding and the enactment of the 21st Century Cures Act
  • What to expect in terms of tax reforms
  • Current developments in the pricing debate

img

Sara Radcliffe

President & CEO
California Life Sciences Association
img

Marc Schwabish

US Head, Pharma Business Development & Licensing
Bayer

1:1 Partnering

10:20 AM - 10:50 AM 1:1 Partnering

General Session

10:50 AM - 11:20 AM Morning Refreshment Break

1:1 Partnering

10:50 AM - 11:20 AM 1:1 Partnering

General Session

11:20 AM - 11:50 AM Panel: The Compelling Future of CNS & Neurodegenerative Diseases

Murali Gopalakrishnan, Senior Director & Head Search & Evaluation Neuroscience, Abbvie Steven Bartz, Director, Worldwide Licensing, Merck & Co.
What is the emerging science in the space?
Where are the most interesting opportunities?
What are the transactional challenges to overcome?

img

Murali Gopalakrishnan

Senior Director & Head Search & Evaluation Neuroscience
Abbvie
img

Steven Bartz

Director, Worldwide Licensing
Merck & Co.

1:1 Partnering

11:20 AM - 11:50 AM 1:1 Partnering


img

Jon Kaiser

President & CEO
K-PAX Pharmaceuticals
img

Adi Frish

SVP Business Development & Licensing
RedHill Biopharma
img

Steven Gelone

Chief Scientific Officer & Head, Business Development
Nabriva Therapeutics

1:1 Partnering

11:50 AM - 12:35 PM 1:1 Partnering

12:35 PM - 1:35 PM Luncheon

1:35 PM - 2:05 PM Biotech Spotlights

Volker Schellenberger, President & CEO, AMUNIX

img

Volker Schellenberger

President & CEO
AMUNIX
Constructing a compelling pitch deck
Keys to moving the dialogue forward
Providing substantive evidence for opportunities

img

Monica Viziano

Senior Director, Alliance Management
Gilead
img

Robert Bagdorf

Vice President of Worldwide Business Development
Pfizer Inc.
img

Michael Bayewitch

Senior Director, Global S&E, Biologics
Teva Pharmaceuticals
img

Kia Motesharei

VP, Global Head of Business Development, Neurology & Immunology Global Busi
EMD Serono
With a few companies leading the space, are there opportunities for others?
What are the more mature opportunities for therapy and new technology?
What are the outcomes to expect in the coming year?

img

Hemmie Chang

Chair, Licensing & Strategic Alliances Practice Group
Foley Hoag
img

Greg Fond

Director, External Innovation
Sanofi
img

Sue Washer

President & CEO
AGTC
img

Peter Nell

VP, Head Strategy & Business Development
Casebia Therapeutics

1:1 Partnering

2:35 PM - 3:05 PM 1:1 Partnering

General Session

3:05 PM - 3:35 PM Afternoon Refreshment Break

1:1 Partnering

3:05 PM - 3:35 PM 1:1 Partnering

General Session

3:35 PM - 4:35 PM Biotech Spotlights

1:1 Partnering

3:35 PM - 4:35 PM 1:1 Partnering

Current increased spinout interest from large and small pharma
What distinguishes deals that succeed from those that don’t?
How to incentivize investors, licensors, and employees for buy-in?


Moderated by Back Bay Life Science Advisors

img

Michael Johnson

VP, Business Development
Eli Lilly
img

Sanjay Mistry

Head of External Value Creation, Janssen
Pharmaceutical Companies of Johnson & Johnson
img

Christoph Pittius

VP, Head of Transactions
AstraZeneca
img

Alex Rabiee

Director, Business Development
Amgen

1:1 Partnering

4:35 PM - 5:05 PM 1:1 Partnering

5:05 PM - 6:05 PM Sunset Soiree

6:05 PM - 11:59 PM End of Day One